Syntara (ASX: SNT) is an Australian pharmaceutical research company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. 

Syntara is developing its drug PXS-5505 for the bone marrow cancer myelofibrosis which causes a build up of scar tissue that leads to loss of production of red and white blood cells and platelets. The US Food and Drug Administration has granted Orphan Drug Designation to PXS-5055 for the treatment of myelofibrosis and permission under an Investigational Drug Application (IND) to progress a phase 1c/2 clinical trial that is scheduled to begin recruitment in Q1 2021. PXS‐5505 is also being investigated as a potential treatment for other cancers such as liver and pancreatic cancer.

Other drug candidates being developed from Syntara's amine oxidase chemistry platform are targeting fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis; fibrotic scarring from burns and other trauma; and inflammatory diseases such as Duchenne Muscular Dystrophy. 

Syntara is listed on the Australian Securities Exchange under the ticker SNT. Its head office and research facilities are in Sydney, Australia.

Biotechnology

Health Services

Medical Devices

Pharmaceutical

Syntara

Gary Phillips

Jim Keary

Simon Green

Jana Baskar

Research and Development Team

Medical Affairs Team

Leadership Team

Syntara

Org chart

Teams

Research and Development Team

Medical Affairs Team

Leadership Team

Similar companies